ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

IGX Intelgenx Technologies Corp

0.58
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Intelgenx Technologies Corp TSXV:IGX TSX Venture Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.58 0.54 0.65 0 01:00:00

IntelGenx to Report Fourth Quarter and Full-Year 2018 Financial Results on March 25, 2019 – Conference Call to Follow

18/03/2019 8:00pm

GlobeNewswire Inc.


Intelgenx Technologies (TSXV:IGX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Intelgenx Technologies Charts.

IntelGenx Technologies Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) today announced that it will release its fourth quarter and full year 2018 financial results after market close on March 25, 2019.

An accompanying conference call will be hosted by Dr. Horst G. Zerbe, President and Chief Executive Officer, and Mr. Andre Godin, Executive Vice-President and Chief Financial Officer, to discuss the results and provide a business update. Details of the conference call and webcast are below:

Date: Monday, March 25, 2019

Time: 8:00 a.m. EDT

Conference dial-in: (833) 231-8269

International dial-in: (647) 689-4114

Conference ID: 1297963

Webcast Registration: Click here

Following the live call, a replay will be available on the Company's website, www.intelgenx.com, under "Investor Relations".

About IntelGenx:

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information about the company can be found at www.intelgenx.com.

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.  Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source:  IntelGenx Technologies Corp.

For more information, please contact:

Stephen Kilmer
Investor Relations 
(514) 331-7440 ext 232
stephen@intelgenx.com

Or

Andre Godin, CPA, CA
Executive Vice-President and CFO
IntelGenx Corp.
(514) 331-7440 ext 203
andre@intelgenx.com

1 Year Intelgenx Technologies Chart

1 Year Intelgenx Technologies Chart

1 Month Intelgenx Technologies Chart

1 Month Intelgenx Technologies Chart

Your Recent History

Delayed Upgrade Clock